Clean Science and Technology Ltd.
CLEANCommodities filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
21 transcript(s)/analyst meet(s) served; 0 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (2 of 21 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20210813 | 2020-06-30 | yes | |
| TRANSCRIPT | 20220602 | 2021-03-31 | yes | |
| TRANSCRIPT | 20211118 | 2021-09-30 | yes | |
| ANALYST_MEET | 20220214 | 2021-12-31 | yes | |
| TRANSCRIPT | 20220801 | 2022-06-30 | yes | |
| TRANSCRIPT | 20230808 | 2022-06-30 | yes | |
| TRANSCRIPT | 20221028 | 2022-09-30 | yes | |
| TRANSCRIPT | 20230208 | 2022-12-31 | yes | |
| TRANSCRIPT | 20230523 | 2023-03-31 | yes | |
| TRANSCRIPT | 20240803 | 2023-06-30 | yes | |
| TRANSCRIPT | 20231104 | 2023-09-30 | yes | |
| TRANSCRIPT | 20240206 | 2023-12-31 | yes | |
| TRANSCRIPT | 20240517 | 2024-03-31 | yes | |
| TRANSCRIPT | 20241111 | 2024-09-30 | yes | |
| TRANSCRIPT | 20250203 | 2024-12-31 | yes | |
| TRANSCRIPT | 20250526 | 2025-03-31 | yes | |
| TRANSCRIPT | 20250719 | 2025-06-30 | yes | |
| TRANSCRIPT | 20251111 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260204 | 2025-12-31 | yes | |
| TRANSCRIPT | 20260520 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260806 | 2026-06-30 | yes |
CLEAN
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.
| Last close | 815.45 |
| 52-week range | 656.4 – 1127.7 |
| Return 1M | -0.78% |
| Return 3M | 4.67% |
| Return 1Y | -27.69% |
| Return 3Y | -42.25% |
| Return 5Y | -60.22% |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 268.00 |
| Other income | 22.00 |
| Total income | 291.00 |
| Cost of materials consumed | 127.00 |
| Purchases of stock-in-trade | 0.00 |
| Changes in inventories | -22.00 |
| Employee benefit expense | 17.00 |
| Finance costs | 0.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.51 | 0.00 |
| institutions foreign | 0.13 | -0.00 |
| institutions domestic | 0.16 | -0.01 |
| mutual funds | 0.12 | -0.00 |
| public | 0.49 | 0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| ANALYST_MEET | 2021-12-31 | 1 |
| TRANSCRIPT | 2026-06-30 | 20 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 248.00 | 237.00 | 217.00 | 188.00 | 181.00 | 195.00 | 228.00 | 224.00 | 238.00 | 241.00 | 264.00 | 243.00 | 245.00 | 220.00 | 249.00 | 268.00 |
| Other income | 3.00 | 13.00 | 13.00 | 13.00 | 6.00 | 8.00 | 14.00 | 10.00 | 11.00 | 5.00 | 12.00 | 13.00 | 7.00 | 10.00 | 3.00 | 22.00 |
| Total income | 250.00 | 250.00 | 229.00 | 202.00 | 187.00 | 203.00 | 242.00 | 234.00 | 249.00 | 246.00 | 276.00 | 256.00 | 251.00 | 229.00 | 252.00 | 291.00 |
| Cost of materials consumed | 94.00 | 74.00 | 69.00 | 64.00 | 67.00 | 71.00 | 80.00 | 88.00 | 93.00 | 90.00 | 97.00 | 93.00 | 85.00 | 83.00 | 99.00 | 127.00 |
| Purchases of stock-in-trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in inventories | -2.00 | 4.00 | -5.00 | 9.00 | -6.00 | -6.00 | -2.00 | -11.00 | -4.00 | -2.00 | -2.00 | -9.00 | 11.00 | 4.00 | -8.00 | -22.00 |
| Employee benefit expense | 11.00 | 12.00 | 13.00 | 12.00 | 12.00 | 12.00 | 13.00 | 13.00 | 14.00 | 14.00 | 15.00 | 15.00 | 14.00 | 15.00 | 4.00 | 17.00 |
| Finance costs | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation and amortisation | 9.00 | 9.00 | 10.00 | 11.00 | 11.00 | 11.00 | 13.00 | 16.00 | 18.00 | 18.00 | 17.00 | 19.00 | 19.00 | 19.00 | 21.00 | 21.00 |
| Other expenses | 47.00 | 40.00 | 35.00 | 28.00 | 33.00 | 32.00 | 42.00 | 39.00 | 45.00 | 40.00 | 48.00 | 44.00 | 48.00 | 46.00 | 59.00 | 50.00 |
| Total expenses | 159.00 | 138.00 | 122.00 | 123.00 | 118.00 | 119.00 | 146.00 | 145.00 | 166.00 | 161.00 | 176.00 | 162.00 | 176.00 | 167.00 | 174.00 | 193.00 |
| Profit before exceptional items and tax | 92.00 | 112.00 | 108.00 | 79.00 | 69.00 | 83.00 | 95.00 | 89.00 | 83.00 | 85.00 | 100.00 | 95.00 | 75.00 | 63.00 | 78.00 | 98.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 92.00 | 112.00 | 108.00 | 79.00 | 69.00 | 83.00 | 95.00 | 89.00 | 83.00 | 85.00 | 100.00 | 95.00 | 75.00 | 63.00 | 78.00 | 98.00 |
| Current tax | 24.00 | 26.00 | 22.00 | 18.00 | 17.00 | 19.00 | 22.00 | 24.00 | 22.00 | 26.00 | 25.00 | 25.00 | 23.00 | 17.00 | 23.00 | 21.00 |
| Deferred tax | -0.00 | 2.00 | 5.00 | 2.00 | 1.00 | 1.00 | 3.00 | -1.00 | 2.00 | -6.00 | 0.00 | -0.00 | -4.00 | -1.00 | -3.00 | 3.00 |
| Tax expense | 24.00 | 28.00 | 27.00 | 20.00 | 17.00 | 20.00 | 25.00 | 23.00 | 24.00 | 20.00 | 25.00 | 24.00 | 19.00 | 17.00 | 19.00 | 24.00 |
| Profit for the period | 68.00 | 84.00 | 81.00 | 59.00 | 52.00 | 63.00 | 70.00 | 66.00 | 59.00 | 66.00 | 74.00 | 70.00 | 55.00 | 46.00 | 58.00 | 73.00 |
| Profit attributable to owners | 68.00 | 0.00 | 81.00 | 59.00 | 52.00 | 63.00 | 70.00 | 66.00 | 59.00 | 0.00 | 74.00 | 70.00 | 0.00 | 0.00 | — | 0.00 |
| Profit attributable to non-controlling interests | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 |
| Other comprehensive income | -0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total comprehensive income | 68.00 | 84.00 | 81.00 | 59.00 | 52.00 | 63.00 | 70.00 | 66.00 | 59.00 | 66.00 | 74.00 | 70.00 | 55.00 | 46.00 | 58.00 | 73.00 |
| Earnings per share, basic | 6.40 | 7.89 | 7.58 | 5.55 | 4.91 | 5.89 | 6.61 | 6.21 | 5.53 | 6.18 | 6.97 | 6.59 | 5.22 | 4.32 | 5.48 | 6.90 |
| Earnings per share, diluted | 6.39 | 7.88 | 7.58 | 5.55 | 4.91 | 5.89 | 6.61 | 6.20 | 5.53 | 6.18 | 6.97 | 6.59 | 5.21 | 4.32 | 5.48 | 6.90 |
Annual results, as filed
| Line | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|---|
| Revenue from operations | 685.00 | 936.00 | 791.00 | 967.00 | 957.00 |
| Other income | 30.00 | 30.00 | 41.00 | 39.00 | 33.00 |
| Total income | 715.00 | 966.00 | 833.00 | 1,005.00 | 989.00 |
| Cost of materials consumed | 245.00 | 338.00 | 283.00 | 368.00 | 360.00 |
| Purchases of stock-in-trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in inventories | -20.00 | -12.00 | -6.00 | -18.00 | -2.00 |
| Employee benefit expense | 35.00 | 45.00 | 49.00 | 56.00 | 48.00 |
| Finance costs | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 |
| Depreciation and amortisation | 25.00 | 36.00 | 46.00 | 69.00 | 78.00 |
| Other expenses | 126.00 | 163.00 | 134.00 | 172.00 | 196.00 |
| Total expenses | 410.00 | 570.00 | 506.00 | 648.00 | 679.00 |
| Profit before exceptional items and tax | 305.00 | 396.00 | 326.00 | 357.00 | 310.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 305.00 | 396.00 | 326.00 | 357.00 | 310.00 |
| Current tax | 73.00 | 98.00 | 76.00 | 97.00 | 88.00 |
| Deferred tax | 3.00 | 2.00 | 7.00 | -4.00 | -8.00 |
| Tax expense | 76.00 | 100.00 | 82.00 | 92.00 | 80.00 |
| Profit for the period | 228.00 | 295.00 | 244.00 | 264.00 | 230.00 |
| Profit attributable to owners | 0.00 | 295.00 | 244.00 | 264.00 | — |
| Profit attributable to non-controlling interests | 0.00 | 0.00 | — | 0.00 | — |
| Other comprehensive income | -0.00 | 0.00 | -0.00 | 0.00 | 0.00 |
| Total comprehensive income | 228.00 | 295.00 | 244.00 | 264.00 | 230.00 |
| Earnings per share, basic | 21.51 | 27.79 | 22.97 | 24.88 | 21.61 |
| Earnings per share, diluted | 21.51 | 27.78 | 22.96 | 24.88 | 21.60 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 1,022.00 | 1,152.00 | 1,231.00 | 1,396.00 | 1,501.00 | 1,608.00 | 1,684.00 | 1,783.00 |
| Non-current assets | 412.00 | 521.00 | 657.00 | 737.00 | 767.00 | 809.00 | 880.00 | 955.00 |
| Current assets | 610.00 | 630.00 | 573.00 | 660.00 | 734.00 | 799.00 | 804.00 | 828.00 |
| Property, plant and equipment | 327.00 | 422.00 | 451.00 | 599.00 | 686.00 | 711.00 | 686.00 | 755.00 |
| Capital work-in-progress | 45.00 | 20.00 | 139.00 | 57.00 | 30.00 | 30.00 | 98.00 | 118.00 |
| Goodwill | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other intangible assets | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 3.00 | 3.00 | 5.00 |
| Inventories | 100.00 | 109.00 | 106.00 | 124.00 | 148.00 | 149.00 | 153.00 | 154.00 |
| Trade receivables | 164.00 | 146.00 | 131.00 | 164.00 | 190.00 | 203.00 | 182.00 | 206.00 |
| Cash and cash equivalents | 49.00 | 12.00 | 5.00 | 10.00 | 11.00 | 20.00 | 5.00 | 28.00 |
| Total equity and liabilities | 1,022.00 | 1,152.00 | 1,231.00 | 1,396.00 | 1,501.00 | 1,608.00 | 1,684.00 | 1,783.00 |
| Equity | 866.00 | 1,010.00 | 1,091.00 | 1,203.00 | 1,297.00 | 1,416.00 | 1,500.00 | 1,584.00 |
| Equity share capital | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 |
| Other equity | 855.00 | 999.00 | 1,080.00 | 1,193.00 | 1,287.00 | 1,406.00 | 1,489.00 | 1,573.00 |
| Total liabilities | 156.00 | 142.00 | 140.00 | 193.00 | 203.00 | 191.00 | 184.00 | 199.00 |
| Non-current liabilities | 18.00 | 26.00 | 29.00 | 33.00 | 40.00 | 36.00 | 35.00 | 34.00 |
| Current liabilities | 138.00 | 116.00 | 111.00 | 160.00 | 163.00 | 156.00 | 150.00 | 165.00 |
| Borrowings, non-current | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Borrowings, current | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Trade payables | 83.00 | 81.00 | 73.00 | 108.00 | 108.00 | 99.00 | 88.00 | 116.00 |
Cash flow, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 127.00 | 279.00 | 117.00 | 237.00 | 103.00 | 214.00 | 154.00 | 275.00 |
| Net cash from investing activities | -103.00 | -270.00 | -93.00 | -186.00 | -70.00 | -152.00 | -127.00 | -203.00 |
| Net cash from financing activities | -33.00 | -55.00 | -32.00 | -53.00 | -31.00 | -53.00 | -42.00 | -64.00 |
| Purchase of property, plant and equipment | 75.00 | 183.00 | 118.00 | 232.00 | 68.00 | 142.00 | 95.00 | 201.00 |
| Net increase in cash | -8.00 | -45.00 | -8.00 | -2.00 | 1.00 | 10.00 | -15.00 | 8.00 |
| con:CFO.BEFORE_TAX | 166.00 | 374.00 | 150.00 | 313.00 | 140.00 | 309.00 | 191.00 | 366.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 38.00 | 94.00 | 34.00 | 75.00 | 37.00 | 95.00 | 37.00 | 91.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 314.00 | 0.00 | 0.00 | 0.00 | 0.00 | 816.00 | 0.00 | 757.00 |
| con:INVESTMENTS_SOLD | 231.00 | 0.00 | 0.00 | 0.00 | 0.00 | 804.00 | 0.00 | 759.00 |
| con:PPE_DISPOSALS | 10.00 | 0.00 | 0.00 | 6.00 | 0.00 | 0.00 | 0.00 | 1.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 78.50 | 74.99 | 74.98 | 74.98 | 74.98 | 74.98 | 74.97 | 74.97 | 74.97 | 74.97 | 0.51 | 0.51 | 0.51 | 0.51 |
| Domestic institutions | 4.76 | 6.40 | 5.23 | 5.14 | 5.04 | 4.55 | 4.77 | 5.46 | 5.76 | 5.92 | 0.19 | 0.20 | 0.17 | 0.16 |
| Mutual funds | — | — | — | — | — | — | — | — | — | 4.56 | 0.13 | 0.14 | 0.12 | 0.12 |
| Insurance companies | 0.37 | 1.17 | 0.50 | 0.48 | 0.71 | 0.86 | 0.97 | 0.99 | 1.04 | 1.07 | 0.04 | 0.05 | 0.04 | 0.04 |
| Foreign institutions | 3.99 | 5.84 | 6.00 | 5.92 | 5.88 | 6.06 | 5.83 | 5.98 | 6.07 | 6.21 | 0.11 | 0.10 | 0.13 | 0.13 |
| Government | — | — | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
| Public | 21.50 | 25.01 | 25.02 | 25.02 | 25.02 | 25.02 | 25.03 | 25.03 | 25.03 | 25.03 | 0.49 | 0.49 | 0.49 | 0.49 |
| Non-institutional | 12.75 | 12.77 | 13.79 | 13.97 | 14.10 | 14.42 | 14.43 | 13.60 | 13.20 | 12.90 | 0.19 | 0.19 | 0.18 | 0.19 |
| Shares outstanding | 106237539 | 106238572 | 106247445 | 106247445 | 106252004 | 106252004 | 106264253 | 106266254 | 106267259 | 106267259 | 106273791 | 106276499 | 106277299 | 106282520 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| Clean Fino-Chem Limited | Wholly Owned Subsidiary Company | Any other transaction, Investment, Purchase of goods | 1,506,290,000.00 | 7 |
| Mr. Ashok Ramnarayan Boob | Key Management Personnel (Managing | Dividend paid, Remuneration | 86,940,000.00 | 2 |
| Mr. Siddhartha Ashok Sikchi | Key Management Personnel (Whole-ti | Any other transaction, Dividend paid, Remuneration | 51,010,000.00 | 3 |
| Mr. Krishnakumar Ramnarayan Boob | Key Management Personnel (Whole-ti | Dividend paid, Remuneration | 36,310,000.00 | 2 |
| Ashokkumar Ramkishan Sikchi HUF | Entities in which KMP are interest | Dividend paid | 31,750,000.00 | 1 |
| Mr. Parth Ashok Maheshwari | Key Management Personnel (Whole-ti | Any other transaction, Dividend paid, Remuneration | 28,520,000.00 | 4 |
| Mrs. Asha Ashok Boob | Relative of Key Management Personn | Dividend paid | 25,740,000.00 | 1 |
| Mrs. Nidhi Mohunta | Relative of Key Management Personn | Dividend paid | 17,730,000.00 | 1 |
| Ashok Ramnarayan Boob HUF | Entities in which KMP are interest | Dividend paid | 17,560,000.00 | 1 |
| Anantroop Financial Advisory Services Private Limited | Entities in which KMP are interest | Dividend paid | 12,500,000.00 | 1 |
| Ms. Shardha Krishnakumar Boob | Relative of Key Management Personn | Dividend paid | 10,270,000.00 | 1 |
| Mrs. Pooja Vivek Navandar | Relative of Key Management Personn | Dividend paid | 10,270,000.00 | 1 |
| Mr. Prasad Krishnakumar Boob | Relative of Key Management Personn | Dividend paid | 10,270,000.00 | 1 |
| Krishnakumar Ramnarayan Boob HUF | Entities in which KMP are interest | Dividend paid | 9,700,000.00 | 1 |
| Matrix Life Science Private Limited | Entities in which KMP are interest | Sale of goods or services | 7,940,000.00 | 1 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-08-06 | Q1FY27 | LIMITED | Read the call |
| 2026-05-20 | Q4FY26 | LIMITED | Read the call |
| 2026-02-04 | Q3FY26 | INR425 per kg, okay., Jason Soans:, TECHNOLOGY LIMITED | Read the call |
| 2025-11-11 | Q2FY26 | SCIENCE AND TECHNOLOGY LIMITED, TECHNOLOGY LIMITED | Read the call |
| 2025-07-19 | Q1FY26 | SCIENCE AND TECHNOLOGY LIMITED, TECHNOLOGY LIMITED | Read the call |
| 2025-05-26 | Q4FY25 | PROMOTER, CLEAN SCIENCE, TECHNOLOGY | Read the call |
| 2025-02-03 | Q3FY25 | Read the call | |
| 2024-11-11 | Q2FY25 | SCIENCE AND TECHNOLOGY LIMITED, TECHNOLOGY LIMITED | Read the call |
| 2024-08-03 | Q1FY24 | SCIENCE AND TECHNOLOGY LIMITED, TECHNOLOGY LIMITED | Read the call |
| 2024-05-17 | Q4FY24 | Read the call | |
| 2024-02-06 | Q3FY24 | SCIENCE AND TECHNOLOGY LIMITED, TECHNOLOGY LIMITED | Read the call |
| 2023-11-04 | Q2FY24 | SCIENCE AND TECHNOLOGY LIMITED, TECHNOLOGY LIMITED | Read the call |
| 2023-08-08 | Q1FY23 | Read the call | |
| 2023-05-23 | Q4FY23 | TECHNOLOGY LIMITED | Read the call |
| 2023-02-08 | Q3FY23 | Read the call | |
| 2022-10-28 | Q2FY23 | Read the call | |
| 2022-08-01 | Q1FY23 | Read the call | |
| 2022-06-02 | Q4FY21 | Read the call | |
| 2022-02-14 | Q3FY22 | Read the call | |
| 2021-11-18 | Q2FY22 | Read the call | |
| 2021-08-13 | Q1FY21 | Read the call |
What they said about it, quarter by quarter
| Topic | Q3FY24 | Q3FY25 | Q3FY26 | Q4FY21 | Q4FY23 | Q4FY24 | Q4FY25 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|
| Capex | Are the products completely prepared in the pilot stage and it's just that this new plant when it starts we are good to go? | So, same equipment of Para Benzoqunone will be converted into Barbituric acid, so no CAPEX, a little bit here and there, but we will start with this n… | I mean I understand both these INR1.5 billion capex, they have been a little bit delayed. | — | First, on the capex, we did INR193 crores this year. | Yes, additional cost will flow in as the new plants also commercialize. | 3.5 crores is the revenue expenditure and balance is capital expenditure, which is one time. | And hence, we are also now in the process of debottlenecking and also putting more capex wherever needed to get into backward integration of these pro… |
| Capital allocation | — | Where we are in the whole customer acquisition cycle? | — | — | — | — | — | — |
| Costs | I mean, the market -- the basic problem that happened because of those issues where there were death of children in South Africa , and there was a tig… | So, we have not increased prices, our prices have still remained at similar levels whereas we continue to see increase in volumes, but of course as yo… | This was particularly in a particular example of 4-MAP because avobenzone 60% of the cost of raw material depends on 4-MAP. | So, one is, see the specialty chemical space is a very interesting space that where raw material prices, when they hike up too much, we do not like to… | But of course, I mean, you can't extrapolate Q4 margins because this quarter, we were benefited with the benign raw material prices also. | Now UV 770 is a three-step process, but UV 944 is a seven-step process, so the raw materials are absolutely different, despite being in the same famil… | — | But also, to be honest, with the capacities of Hydroquinone in China, and they are not as impacted with the raw material prices to that extent, which … |
| Debt and cash | — | We would remain in that narrow range of 24%-25% of sales as a working capital. | I mean, we are healthy in terms of cash flow, company is still sitting on INR450 crores of cash. | And just lastly, on the working capital side, we had seen a slightly sharp reduction last year FY21, while this time there is an increase is that larg… | Sir, on the new set of products, so the HALS series, will our working capital requirement go up? | — | And lastly, on the balance sheet side, working capital has inched up a bit for the full year. | — |
| Demand | I would not know exactly the 10 products, but yes the major HALS which we have mentioned, they will all be in pipeline. | We had a lot of proposals in pipeline, but we have shortlisted whom we want to work. | If I look at the Q3 numbers in specific, domestic demand slowdown probably was a bigger factor here. | However, this is the first year where we have got 70% of their global demand, and we have got their contract for three years. | But also, the overall global demand is slightly reducing because of Europe factor, because of the U.S. factor. | Second follow up on 701 Siddharth, I thought earlier we thought it was Agro Intermediate and that is where the large demand was there for 701 and now … | So, when we said the majority of the 2,000, 1,900 tons volume that we sold is in domestic, and does it mean that we have largely saturated the domesti… | How do you see the demand and supply scenario over there? |
| Guidance | — | Our product from lab and pilot has been approved by large customer like Sudarshan Chemical and we expect to begin this production of Barbituric acid i… | So I just wanted to know, sir, I mean, according to your internal -- I mean, calculations, how much revenue do we expect these -- both these projects … | Sir, but do we expect to pass on this entire cost, or we expect the prices to normalize, wait for what happens with the commodity and probably then ta… | Second, on the margin guidance and what we have delivered, I remember it probably the end of second quarter, we guided like we will be stable at 40%. | And this CFCL is commercialized in March 24 okay, so how much we expect the topline growth and EBITDA margin from the CFCL? | 425 that we are making at this point, should we expect that to improve significantly in the next couple of years as the business ramps us? | And given the traction now, your earlier guidance of, let's say, optimal utilization in 3 years, that stands or probably we can look at -- we will be … |
| Margin | And second, Siddharth, I can appreciate the percentage margin and which are very healthy. | Is that the reflection of gross margins quarter-on-quarter improving or is it because phenol prices have slightly fallen down, so without price increa… | Is there further sort of scope for us to probably improve our costing in terms of improving the margins or probably it's only the operating leverage, … | So, for BHA which is the most margin accretive product in our portfolio, we have witnessed around 50% volume growth and around small 7% to 8% as reali… | Sanjesh, in terms of margin for parent company, there will be relatively steady state of margin. | That I got from the margin perspective that will play out from the cost perspective there is more cost which is yet to be recognized in the P&L? | Phase-2 will be far more pointed because we will not get into products which are lower margin accretive compared to the higher series. | See, I can tell you you have seen quarter 3, we were EBITDA neutral. |
| People | Last question on the utilization side... | Now coming to MEHQ, P-BQ and TBHQ, MEHQ, what has been the utilization based on capacity? | But to just pinpoint with the Performance Chemical 1 because of the prices reduction overall, the -- around 80% capacity utilization, we are looking a… | — | I mean, the plant will be of these sizes, but of course, gaining the market share and utilization will take about three to four years' time. | And just another one if you can help me with the capacity utilization for our MeHQ and BHA? | See, once we start getting majority of approvals globally, once we start seeing decent ramp up, when we start seeing that okay we are seeing about 60%… | Just what I'm trying to understand is if our utilization levels reach certain threshold so that we can actually breakeven within these 2 quarters or y… |
| Pricing | First, on your opening remarks you said that there has been a lot of capacities which have come in China and put a pressure on pricing. | My question is on we were planning to take some price hike somewhere post December. | Given what you already share on the China bit as well, the pricing in the overall, let's say, HQ value chain. | In case of coal, we have seen the price increase by 77%, so that has led to power and fuel costs increasing by around 106% on year-on-year basis. | Obviously, this has three components; the exchange rate, the rupee depreciation aspect, pricing has clearly helped as compared to '22, and then the vo… | Pricing how much discount it would be today to the imported pricing? | — | So how should we see the pricing competitiveness for us and the ability to pass on in the market, considering that we are a new kid on the block? |
| Revenue growth | — | — | When can we see the margin that we used to do around -- revenue growth that we had around '21 to '23 could come back? | — | We had a stellar year for the top end growth of close to 35 percentage. | See typically if you see our past record, this is as per our past record, our asset turn has been close to 2.5 to 2.7, so based on the investment whic… | — | How should we see the EBITDA and revenue growth in FY27? |